The present study examines the nature of humoral and cellular immune reconstitution in 28 patients with advanced breast cancer following high-dose chemotherapy with stem cell rescue. Patients underwent testing of T, B, NK and dendritic cell function at serial time points until 1 year post transplant or until the time of disease progression. Abnormalities in T cell phenotype and function were observed following high-dose chemotherapy that persisted for at least 6-12 months. The vast majority of patients experienced an inversion of the CD4/CD8 ratio and demonstrated an anergic response to candida antigen. Mean T cell proliferation in response to PHA and to co-culture with allogeneic monocytes was significantly compromised. In contrast, mean IgG and IgA levels were normal 6 months post transplant and NK cell yields and function were transiently elevated following high-dose chemotherapy. Dendritic cells generated from peripheral blood progenitors displayed a characteristic phenotype and were potent inducers of allogeneic T cell proliferation in the posttransplant period. The study demonstrates that patients undergoing autologous transplantation for breast cancer experience a prolonged period of T cell dysfunction. In contrast, B, NK, and DC recover more rapidly. These findings carry significant implications for the design of post-transplant immunotherapy. Bone Marrow Transplantation (2000) 26, 169-176.
The use of high-dose chemotherapy with stem cell rescue is associated with complete or near complete remissions in the majority of patients with advanced breast cancer. 1, 2 However, subsequent disease progression is commonly seen due to the persistence of chemotherapy-resistant clones. A major focus of clinical research is the use of immunotherapy following stem cell transplantation in an effort to eradicate minimal residual disease. Gaining a greater understanding of immune reconstitution in patients with breast cancer who have undergone stem cell transplantation is essential in assessing their risk for infectious complications as well as the design of post-transplant immunotherapeutic strategies.
The nature of immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer has not been fully evaluated. Prior studies have focused on the immune recovery of patients with hematological malignancies who have undergone autologous or allogeneic transplantation. [3] [4] [5] [6] [7] [8] [9] These studies demonstrate that patients undergo a prolonged period of immune dysfunction in the post-transplant period that persists long after the recovery of hematopoiesis.
Immune dysfunction following hematopoietic cell transplantation arises from quantitative and qualitative abnormalities in B and T cell populations which, in the absence of chronic graft-versus-host disease (cGVHD), largely resolve in 6-12 months. 3 The number of circulating CD3 ϩ T cells recovers shortly after allogeneic or autologous transplantation but patients experience prolonged inversion of the CD4/CD8 ratio due to the relative absence of T helper cells and the increased presence of CD8 ϩ suppressor cells. [10] [11] [12] [13] [14] [15] In vitro T cell proliferation and IL-2 production in response to anti-CD3, IL-2 and allogeneic lymphocytes is significantly blunted for 6-12 months following transplant. [16] [17] [18] [19] Delayed type hypersensitivity reactions to recall antigens are largely absent and recover only in the absence of cGVHD. In contrast, a period of heightened NK cell activity has been found in the immediate post-transplant period. 3 Abnormalities in humoral immunity have also been noted in the post-transplant period. Levels of IgG and IgM are suppressed for 6-12 months post transplant, while recovery of serum levels of IgG2, IgG4 and IgA levels may be delayed for several years. 2, 20, 21 Antibody responses to neoantigens such as KLH or pneumococcal polysaccharide is largely absent for the first 3 months following transplant. Proliferative responses to B cell mitogens are blunted for several months post transplant.
The nature of the recovery of dendritic cells (DC) following hematopoietic transplantation has not been explored. DC are potent antigen presenting cells that are essential for the initiation of primary cellular immune responses. 22, 23 They derive their potency from the rich expression of MHC class I, class II, costimulatory and adhesion molecules necessary for the activation of antigen-specific T cell responses. [24] [25] [26] DC manipulated to present tumor antigens have been used to generate tumor vaccines and have been associated with disease regression in animal models and clinical studies. [27] [28] [29] [30] [31] [32] [33] [34] [35] As such, a focus of research has been the incorporation of DC-based immunotherapy into the post-transplant period.
In the present study we sought to characterize the nature of immune reconstitution in patients with advanced breast cancer who had undergone high-dose chemotherapy with peripheral blood stem cell rescue. The results demonstrate that patients experience a prolonged period of T cell dysfunction that persists for at least 1 year post transplant. In contrast, immunoglobulin production and NK cell activity recovers more rapidly and dendritic cells exhibit normal phenotype and function in the immediate post-transplant period.
Materials and methods

Patient selection and treatment regimen
Patients with metastatic breast cancer or locally advanced disease (stage III or stage II with у10 axillary lymph nodes involved with invasive carcinoma) were enrolled from April 1997 to August 1998. As per protocol, patients met established eligibility criteria for high-dose chemotherapy including the absence of disease progression while receiving pre-transplant induction chemotherapy, the absence of significant co-morbid medical disease, and the demonstration of adequate organ function as measured by laboratory analysis, pulmonary function tests and assessment of cardiac ejection fraction. Patients were treated with three to six cycles of standard-dose induction chemotherapy prior to study entry. Patients subsequently underwent stem cell mobilization with cyclophosphamide 3 g/m 2 followed by GM-CSF at 5 g/kg/day for 1 week, and then GM-CSF and G-CSF each at 5 g/kg/day until completion of collections. The transplant regimen consisted of cyclophosphamide 6 g/m 2 , thiotepa 500 mg/m 2 and carboplatin 800 mg/m 2 given by continuous infusion. 36 Serial measurements of immune function were performed prior to stem cell mobilization, and at 1, 3, 6, 9 and 12 months post transplant.
Delayed type hypersensitivity reactions (DTH)
DTH reactivity to candida antigen was determined as a measure of in vivo T cell function. Candida albicans antigen for skin testing was made from culture filtrate and cells of two strains of Candida albicans (Allermed Laboratories, San Diego, CA, USA). The fungi were propagated in a chemically defined medium consisting of inorganic salts biotin and sucrose. A lyophilized source of material was extracted with a solution of 0.25% NaCl, 0.0125% NaHCO 3 , 0.03% albumin USP, 8 ppm polysorbate 80 and 0.4% phenol. 0.1 ml was administered as a superficial intradermal injection at serial time points. Local induration of the skin was measured 48 h after injection. A response of 5 mm was considered positive.
T cell subsets
CD4/CD8 subsets analyses were performed in the clinical flow cytometry laboratory at Beth Israel Deaconness Medical Center. Peripheral blood was obtained at serial time points and cocultured with fluorochrome-labeled antibodies directed against CD45/CD3/CD4 and CD45/CD3/CD8 (Tritest; Becton Dickinson, Franklin Lakes, NJ, USA). The percentage of total lymphocytes that express CD4 and CD8 was determined by FACS analysis and the absolute number of CD4 and CD8 cells as well as the CD4/CD8 ratio was determined.
PHA-mediated T cell stimulation
Peripheral blood mononuclear cells (PBMC) were isolated from patients at serial time points by subjecting peripheral blood to Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) density gradient centrifugation (d = 1.077, 400 g). Cells were suspended in RPMI 1640 medium containing 10% heat-inactivated human AB serum (Sigma, St Louis, MO, USA), 2 mm l-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin for 1 h. Nonadherent cells rich in T cells were harvested and seeded in 96-well plates at a concentration of 1 ϫ 10 5 cells/well. PHA (Roche Diagnostics, Basel, Switzerland) was added at a concentration of 2 g/ml. Cell cultures were maintained at 37°C with 5% CO 2 . After 3 days of culture, T cell proliferation was determined by measuring thymidine incorporation after the addition of 0.5 Ci/well of 
Stimulation of T cells with allogeneic monocytes
Nonadherent PBMC rich in T cells were isolated from patients at serial time points as outlined above. PBMC isolated from buffy coat preparations that had been obtained from healthy donors were used to generate peripheral blood monocytes. Nonadherent cells were removed with repeated washes with RPMI 1640 medium. The strongly adherent cells represented a mature monocyte population and were maintained in media with human sera in the absence of cytokines. 1 ϫ 10 5 nonadherent PBMC isolated from patients were cocultured for 5 days with 2.5 ϫ 10 4 monocytes in 96-well round bottom plates in a final volume of 200 l of RPMI 1640 with 10% human serum at 37°C with 5% CO 2 . T cell proliferation was determined by measuring thymidine incorporation after the addition of 0.5 Ci/well 
Quantitation and functional assessment of NK cells
NK cells were quantified for a subset of patients by determining the percentage of peripheral blood lymphocytes that were CD3 − /CD56 ϩ using FACS analysis. Nonadherent PBMC were cultured for 48 h in the presence of 500 U/ml of IL-2 (Collaborative Biomedical, Bedford, MA, USA). The cells were then cocultured for 4 h with the NK sensitive cell line, K562, at effector to target ratios of 25:1, 10:1 and 5:1. Lysis was determined by measuring LDH release by the Cyto Tox 96 assay (Promega, Madison, WI, USA). Percent lysis was calculated by the formula: % cytotoxicity = sample release − effector spontaneous release − target spontaneous release target maximum release − target spontaneous release
Generation of dendritic cells
PBMC were suspended in RPMI 1640 medium containing 10% heat-inactivated human AB serum, 2 mm l-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin for 1 h. Nonadherent cells were removed and the adherent cells were placed in medium containing 1000 units/ml GM-CSF (Immunex, Seattle, WA, USA) and 1000 units/ml IL-4 (Genzyme, Boston, MA, USA) for 1 week at 37°C with 5% CO 2 . The cells were then harvested for phenotypic and functional analyses.
Monoclonal antibodies and FACS analysis
Phenotypic characterization of the dendritic cell populations after in vitro culture was performed using monoclonal antibodies (Mabs) specifically reactive with the following cell surface antigens: CD14, CD1a, CD80, CD86, CD83, CD54, CD40 and HLA-DR (Coulter, Miami, FL, USA). Cells were incubated with primary murine antihuman antibody for 30 min on ice. After two washes, the cells were incubated with a secondary goat anti-murine antibody conjugated with FITC (Sigma) for indirect fluorescence labeling. Cells were then washed, fixed with 2% paraformaldehyde and evaluated by flow cytometric analysis. 
Mixed lymphocyte reaction (MLR) studies
Statistical design
Descriptive statistics were generated separately by time of assessment for each immunological measure. Median and mean values Ϯ standard error are reported. CD4/CD8 ratio, DTH, PHA response, IgA, and IgG levels are also dichotomized and reported as percent of patients expressing a normal value. These dichotomized endpoints were compared at months 1, 3 and 6 post transplant between metastatic cancer vs locally advanced disease using Fisher's exact test. Time to recurrence was computed from the date of BMT, and median time to recurrence was calculated from the
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Kaplan-Meier survival plot. As an exploratory analysis, we examined the predictive value of the CD4, CD8, PHA and DTH at 3 months (both as continuous and dichotomized endpoints) on time to recurrence using Cox's proportional hazards model.
Results
Twenty-eight patients (19 with metastatic cancer and nine with locally advanced disease) undergoing high-dose chemotherapy with stem cell rescue were enrolled from April 1997 to August 1998. Seven of nine patients with locally advanced disease presented with inflammatory breast cancer. Disease characteristics and history of prior treatment regimens are outlined in Table 1 . Patients underwent serial immunological assessments prior to high-dose therapy and at 1, 3, 6, 9 and 12 months post transplant. The mean and median follow up was 12.5 and 12.8 months, respectively. Nine patients were taken off study after developing progressive disease at 6-12 months post transplant and one patient moved out of the area after 6 months of follow-up.
DTH
The DTH responses following intradermal injection of Candida antigen was determined at serial time points as a measure of T cell function in vivo (Figure 1 ). Patients developing an area of induration of у5 mm were considered to have an intact response. A positive DTH response to candida antigen was seen in 85% of patients prior to undergoing high-dose chemotherapy. In contrast, only 32% of patients demonstrated an intact response 1 month following transplantation. A gradual increase in the percentage of patients with positive reactions was seen over time with 38, 45, 58 and 80% of patients demonstrating a normal response at 3, 6, 9 and 12 months post transplant, respectively. One year after transplant, 20% of patients remained anergic. At 1 month post transplant, 60% of patients with locally advanced disease demonstrated a positive DTH response as compared to 16% of those with metastatic disease (P = 0.03).
CD4/CD8
Prior to high-dose chemotherapy, all patients had a normal CD4/CD8 ratio as defined by a value у1.0 (Figure 2a) . Following autologous transplantation, the vast majority of patients experienced an inversion of the CD4/CD8 ratio with 23 and 14% of patients demonstrating a normal CD4/CD8 ratio at 1 and 3 months post transplant, respectively. After 9 months, only 50% of patients had a normal ratio and at 12 months 90% of patients had recovered. The pre-transplant mean and median levels of CD4/CD8 ratio were 2.2 and 1.8, respectively, while at 3 months post transplant they were each 0.7 representing a 70-75% decrease from pre-transplant levels (Figure 2b ). Although the mean and median CD4/CD8 ratio exceeded 1.0 at 9 months post transplant neither value had recovered to the pre-transplant level after 1 year. There was no statistical difference between patients with metastatic and locally advanced disease with regard to the percentage of patients with a CD4/CD8 Ͼ1.0 at 3 or 6 months post transplant (P = 1.0 and 0.1, respectively).
PHA response
PHA-induced T cell proliferation was measured at serial time points to determine if T cell reactivity to mitogenic stimulation is compromised following high-dose chemotherapy (Figure 3a) . Prior to transplantation, 81% of patients demonstrated an intact response to stimulation with 2 g/ml of PHA as defined by tritiated thymidine uptake у30 000 c.p.m. In contrast, only 35% achieved a similar level of response at 1 month post transplant. A gradual increase in the percentage of patients demonstrating intact PHA responses was seen with increasing time post transplantation with 42%, 46%, 43% and 60% demonstrating an intact response at 3, 6, 9 and 12 months, respectively. The mean and median level of tritiated thymidine uptake prior to transplant was 91 000 and 93 000 c.p.m., respectively (Figure 3b ). One month post transplant these values fell to 23 000 and 11 000 c.p.m., respectively. A gradual increase was seen over the first year following transplant. However, even 1 year post transplant the level of response did not reach pre-transplant levels.
T cell response to allogeneic monocytes
T cell proliferation in response to co-culture with allogeneic monocytes derived from normal volunteers was measured pre-transplant and at serial time points following high-dose chemotherapy. Prior to high-dose therapy, the mean value was 23 000 c.p.m. Following transplantation, T cell proliferation was blunted and remained compromised for the entire 1 year period of follow-up ( Figure 4) . Ten patients demonstrated a significant reactivity in the pre-transplant period as defined by tritiated thymidine uptake of Ͼ10 000 c.p.m., (mean level of 51 500 Ϯ standard error 12 800). One month post transplant, a sharp reduction in the degree of T cell proliferation was observed in this group of patients with a mean level of 5000 c.p.m. (mean level 5000 Ϯ standard error 1500). 
NK cell recovery
A subgroup of patients underwent serial quantitation of NK cells using flow cytometric analysis of peripheral blood mononuclear cells ( Figure 5 ). Prior to autologous transplantation, CD3 − /CD56 ϩ cells comprised 12% of the lymphocyte population (range 5.5-17%). A transient increase in the percentage of NK cells was seen 1 month post transplant with 20% of lymphocytes found to be CD3 − /CD56 ϩ (range 4-50%). A return to pre-transplant levels was subsequently seen with CD3 − /56 ϩ cells comprising 12% and 11% of lymphocytes at 3 and 6 months post transplant, respectively. PBMC lysis of the NK sensitive K562 cell line was performed in a subgroup of patients at various time points post transplant as a measure of NK cell functional activity. The mean lysis observed in four patients tested Ͻ6 months post transplant was 39%, while the mean value for six patients tested at 6-12 months post transplant was 30%.
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Immunoglobulin levels
The majority of patients were found to have normal levels of circulating IgG and IgA prior to transplant (Table 2) . Eighty-five per cent of patients had a IgG level Ͼ600 mg/dl pre-transplant while 73% maintained this level at 6 months Table 2 Immunoglobulin levels
Prior to stem cell 6 months post transplant transplant (27 (23 patients post transplant ( Table 2 ). The mean and median level was 798 mg/dl and 715 mg/dl pre-transplant and 803 mg/dl and 833 mg/dl, post transplant respectively. Ninety-three and 91% of patients had an IgA level Ͼ60 mg/dl pre-transplant and 6 months following transplant, respectively. The mean IgA titer was 162 mg/dl and 141 mg/dl pre-transplant and 6 months post transplant, respectively.
Dendritic cell recovery
DC were generated from precursor populations in the peripheral blood pre-transplant and at serial time points following high-dose chemotherapy. Adherent mononuclear cells were isolated and cultured for 1 week with GM-CSF and IL-4. The cells were then harvested for phenotypic and functional assessment. FACS analysis revealed a characteristic DC phenotype with prominent expression of class II, costimulatory (CD40, CD80, CD86), and adhesion (CD54) molecules as well as modest expression of CD83, a relatively specific DC marker ( Figure 6 ). Prior to stem cell transplant, DC generated from peripheral blood progenitors were potent stimulators of the alloMLR assay with a mean proliferation of 49 000 c.p.m. when T cells were co-cultured for 5 days with the dendritic cell population at a ratio of 30:1 ( Figure 7) . In contrast to deficiencies found in T cell function following transplant, DC maintained their ability to act as effective antigen presenting cells. The capacity of DC generated from peripheral blood precursors to stimulate T cell proliferation was in fact augmented in the post-transplant period. The mean value for MLR reactivity at a T cell:APC ratio of 30:1 was 54 000, 59 000 and 96 000 at 1, 3 and 6 months post transplant, respectively.
Episodes of clinical infection
No severe or life-threatening infections occurred in the patient population following engraftment. Nine self limited infections were reported in seven patients. These included four episodes of upper respiratory infections/bronchitis, two episodes of peumonia, one patient with sinusitis, and two presumed viral infections. A specific organism was not identified in any of these instances and all resolved with oral antibiotics or a period of observation. There was no correlation between the degree of cellular and humoral immune dysfunction and incidence of infection. A majority of the infections occurred at 6-12 months post transplant and not during the period in which immunity was found to be most compromised.
Outcome analysis
The median time to progression was 16 months with a 95% confidence interval of 11-18 months. By univariate analysis, there was no statistical correlation between time to recurrence and the DTH response, CD4/CD8 ratio, and PHA-mediated T cell proliferative response at 1 or 3 months post transplant. 
Discussion
The use of high-dose chemotherapy with stem cell rescue has been pursued in patients with metastatic and locally advanced breast cancer in an attempt to overcome tumor resistance and generate durable remissions. Recent efforts have focused on strategies to amplify immunity post transplant, as well as to develop tumor-specific cellular and humoral immune responses, in an attempt to eliminate persistent disease following high-dose chemotherapy. 37 Understanding the nature of immune reconstitution in this patient population is essential for the design of post-transplant immunotherapy.
The nature of immune reconstitution following hemato- poietic stem cell transplantation has been extensively studied in patients with hematological malignancies who have undergone allogeneic or autologous transplantation. [3] [4] [5] [6] [7] [8] [9] Humoral and cellular immunity is compromised for a minimum of 6-12 months post transplant. Abnormalities have been demonstrated in T and B cell populations characterized by phenotypic immaturity, inversion of CD4/CD8 ratios, deficiencies in immunoglobulin levels, and blunted responses to mitogenic stimuli. In contrast, the impact of hematopoietic transplantation on antigen presenting cells, such as DC, has not been well characterized.
In the present study serial assessment of humoral and cellular immunity was performed in patients with advanced breast cancer who had undergone stem cell transplantation. Although many patients had been heavily pretreated with chemotherapy, cellular immune function prior to transplantation was largely intact as measured by DTH response, CD4/CD8 ratios, and T cell responses to mitogenic stimulation. Despite the lack of serious clinical infection in the post-transplant period, profound deficiencies in T cell function were observed that were only partially reversed 6-12 months following transplantation. In contrast, NK cell function recovered rapidly and a majority of patients demonstrated normal immunoglobulin levels by 6 months post transplant. DC generated in vitro from peripheral blood progenitors demonstrated normal phenotype and function in the early post-transplant period. DC displayed characteristic phenotype with rich expression of costimulatory, adhesion, and class II molecules and potent stimulation of allogeneic T cell proliferation.
The use of DC to generate anti-tumor vaccines has emerged as a promising area of cancer research. [34] [35] [36] [37] DCbased vaccines have resulted in disease responses and may provide an effective strategy to eliminate minimal residual disease following high-dose chemotherapy. The present results demonstrate that DC derived from peripheral blood progenitors in the immediate post-transplant period are immunologically potent and may be an effective tool to Bone Marrow Transplantation generate tumor-specific immunity. However, the efficacy of vaccine-based immunotherapy in the post-transplant period is likely to be compromised by the associated abnormalities in T cell function which persist for 6-12 months following high-dose chemotherapy. The opportunity for intervention during the period of minimal residual disease is therefore limited in that recovery of T cell responsiveness only occurs at a time commonly associated with disease progression. Therefore, strategies to speed T cell reconstitution post transplant are an essential element of designing effective immunotherapeutic approaches in this patient population. Our group is currently exploring the impact of IL-12 and GM-CSF therapy on immune recovery in anticipation of their combined use with tumor-specific vaccine approaches in an effort to eradicate chemotherapy-resistant disease following stem cell transplantation.
